Multikine is a new product being developed by CEL-SCi for front-line use in patients with head and neck cancer. I observed a presentation at the 2015 Biotech Showcase on January 12, 2015. A late stage clinical trial is currently enrolling – Phase III Study of LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only. Continue reading
Category Archives: Traditional Chemotherapy
The Texas 2 Step Approach to Cancer Cyberwarfare via Exosomes
Multi-modality (surgery, chemo, radiation) therapy and combination chemotherapy (e.g, CHOP and ABVD) have long been the mainstays of treating cancer. So, we should not be surprised to read about the discovery made by scientists at Rice University and MD Anderson regarding a two-step approach involving radiation and immunotherapy. Continue reading
Targeted Nanoparticles for Cancer – optimizing physiochemical properties for enhanced tumor-killing
Last week, BIND Therapeutics and Amgen ended a collaboration on a targeted nanaoparticle that employed a proprietary cytotoxic compound from Amgen. However, BIND has several other programs (and partnerships with AstraZeneca, Roche, and Pfizer) that are proceeding in the clinic, which employ its Targeted Nanoparticle (TNP) technology. How does this work? Continue reading
Bi-specific antibodies – matchmaking cancer and T-cells
Amgen reported encouraging data from a 189 patient phase 2 trial at this year’s ASCO meeting on blinatumomab in patients with Philadelphia Chromosome (9,22 translocation) negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) – see http://ecancer.org/conference/514-asco-2014/video/2913/blinatumomab-shown-to-be-beneficial-in-relapsed-refractory-b-precursor-acute-lymphoblastic-leukaemia.php. Continue reading
PARP inhibitor rejected by FDA Advisory Committee, then Approved for refractory patients
In June 2014, the FDA Oncology Drug Advisory Committee voted 11-2 to delay approval of AstraZeneca’s olaparib, a PARP (poly-ADP ribose polymerase) inhibitor for maintenance therapy in patients with ovarian cancer. The product received Accelerate Approval designation from the FDA, which provides for conditional approval pending follow-up studies, based on surrogate endpoints from Phase 2 trials, in this case, progression-free survival (PFS). Continue reading
Nivolumab Phase 3 study stopped early for efficacy
Great news – nivolumab, BMS’ PD-1 immune checkpoint control inhibitor was shown to prolong overall survival when used front-line in patients with advanced melanoma. The study was stopped early, that is before it fully enrolled the planned number of patients, by an independent data monitoring committee because it was shown to be quite effective. Continue reading
Autophagy inhibitors for resistant cancers
Autophagy is a process by which cells that are under stress and deprived of nutrients pause to recycle themselves in order to maintain viability. Autophagosomes comprised of cellular organelles are formed, followed by Lysosomal destruction; the cell then uses the substrates for synthesis and reconstitution. Cells in autophagy do not replicate… Continue reading